select

THE FIRST AND ONLY PPI WITH A DUAL DELAYED RELEASE™ (DDR) FORMULATION, WHICH PROVIDES A SECOND RELEASE OF DRUG

KAPIDEX is the first and only PPI with a Dual Delayed Release™ (DDR) formulation, which results in a dexlansoprazole plasma concentration-time profile with two distinct peaks; the first peak occurs 1 to 2 hours after administration, followed by a second peak within 4 to 5 hours.

Conclusions of comparative efficacy cannot be drawn from this information.

See About KAPIDEX for more information on how the Dual Delayed Release™ (DDR) formulation works.

KAPIDEX IS EFFECTIVE, CAN BE TAKEN WITHOUT REGARD TO FOOD, AND OFFERS A SAFETY AND TOLERABILITY PROFILE SIMILAR TO LANSOPRAZOLE

KAPIDEX 60 mg provided consistently high EE healing rates at week 8.1 KAPIDEX 30 mg provided full 24-hour heartburn relief in a majority of symptomatic non-erosive GERD patients at week 4.1 Clinical studies have shown that KAPIDEX offers a safety and tolerability profile similar to lansoprazole.1 And KAPIDEX can be taken without regard to food.1

  • KAPIDEX should be swallowed whole. Alternatively, capsules can be opened, sprinkled on 1 tablespoon of applesauce, and swallowed immediately
  • While KAPIDEX can be taken without regard to food, some patients may benefit from administering the dose prior to a meal if post-meal symptoms do not resolve under post-fed conditions
  • KAPIDEX 30 mg should be considered for patients with moderate hepatic impairment

For more detail, please see the full Prescribing Information.

Reference: 1. KAPIDEX (dexlansoprazole) package insert, Takeda Pharmaceuticals America, Inc.

KAPIDEX is indicated for:

  • Healing all grades of erosive esophagitis (EE) for up to 8 weeks
  • Maintaining healing of EE for up to 6 months
  • Treating heartburn associated with symptomatic non-erosive gastroesophageal reflux disease (GERD) for 4 weeks

Important Safety Information

  • KAPIDEX is contraindicated in patients with known hypersensitivity to any component of the formulation. Hypersensitivity and anaphylaxis have been reported with KAPIDEX use.
  • Symptomatic response with KAPIDEX does not preclude the presence of gastric malignancy.
  • Most commonly reported treatment-emergent adverse reactions (≥2%): diarrhea (4.8%), abdominal pain (4.0%), nausea (2.9%), upper respiratory tract infection (1.9%), vomiting (1.6%), and flatulence (1.6%).
  • Do not co-administer atazanavir with KAPIDEX because atazanavir systemic concentrations may be substantially decreased. KAPIDEX may interfere with absorption of drugs for which gastric pH is important for bioavailability (e.g., ampicillin esters, digoxin, iron salts, ketoconazole). Patients taking concomitant warfarin may require monitoring for increases in international normalized ratio (INR) and prothrombin time. Increases in INR and prothrombin time may lead to abnormal bleeding and even death. Concomitant tacrolimus use may increase tacrolimus whole blood concentrations.

Please see the full Prescribing Information for KAPIDEX.

This site is intended for US residents only